MET and adenocarcinoma: Nevertheless, the incidence of MET amplification is significantly lower, ranging from 2% to 5% in naïve NSCLC patients, as reported by Colombino et al. in a study performed on 1440 patients with adenocarcinoma [75,103,107,108].